BONESUPPORT: Three Catalysts Landed, the Guidance Didn't Move
A NEJM publication, a final CMS reimbursement ruling and a fresh FDA submission — and still 33–36%. The real argument has migrated to a mouse study.
BONEX.ST · Earnings Call · 2026-10-22
Three catalysts, one unchanged number
On paper, Q3 2026 was the quarter BONESUPPORT has been promising for two years. Net sales of SEK 409 million, up 38% at constant currency; adjusted operating profit of SEK 139 million for a 34% margin; operating cash flow of SEK 138 million; a SEK 510 million cash balance even after SEK 60 million of buybacks. “Q3 reflected solid execution across the business.” — Torbjorn Skold, CEO · 2026-10-22 Then came the part that mattered. “Following combined growth of 33% in constant currencies over the first 3 quarters, we confirm our previously communicated full-year outlook of sales growth between 33% and 36% in constant currency.” — Torbjorn Skold, CEO · 2026-10-22 The sell side did the arithmetic immediately: 33–36% for the year after 38% in Q3 implies anywhere from 32% to 44% in Q4 — a band so wide it stops functioning as a forecast. Erik Cassel asked directly, and got philosophy: “We think it's likely to end up anywhere in that. Otherwise, we wouldn't have provided it.” — Torbjorn Skold, CEO · 2026-10-22 Context matters here. That range was set in July, and it was a cut from the prior "at least 40%" (later "at least 35%") language — a July written question on that call was literally titled "What triggered the downgrade of your guidance for this year?" Three genuine catalysts have since landed. The number has not moved. That is the quiet tension running through the entire call.The keyword map flipped from commercial to clinical
In the third quarter the company's single highest-momentum keyword was CMS ruling. This quarter it is still present but has slid far down the list, while the top of the table is dominated by science: local antibiotic at the very top, SOLARIO, clinical relevance, long duration, treatment failure, antimicrobial resistance. The reason is timing: SOLARIO published in the New England Journal of Medicine on 16 September. Definite treatment failure came in at 14.1% for long systemic courses versus 11.1% for short — non-inferiority met — and the safety side was more striking still: “By week 6 after surgery, symptoms potentially related to the treatment had occurred in 45.2% of the patients in the long duration group and only in 17.2% in the short duration group.” — Michael Diefenbeck, Chief Medical Officer · 2026-10-22 One discipline point management was careful to make: SOLARIO is a class study spanning 17 products including PMMA, with roughly 70% of enrolled patients receiving CERAMENT. It validates local antibiotic therapy, not one molecule. Commercially that is fine — BONESUPPORT holds the only on-label approval in the U.S. category, and the new specific identification codes are tied to on-label use. Intellectually, though, a class-level win is a class-level argument, and the peers can borrow it too. Note the sector echo: XVIVO.ST spent its own call this week leaning on the same clinical evidence currency. This is what medical-device equity stories sound like when the reimbursement logjam clears and the debate moves to proof.The carrot is real this time — just slow
The clearest genuine change this quarter is procedural. In April: “it is a proposed ruling. So it is not -- it has not been approved. It's not been decided on yet.” — Torbjorn Skold, Chief Executive Officer · 2026-04-22 In July: “it's still a proposed ruling... too early to tell.” — Torbjörn Sköld, CEO · 2026-07-16 Now it is final: the FY27 IPPS rule confirmed improved payment for CERAMENT G in orthopedic infection, effective 1 October, 100% inpatient, with dedicated procedure and identification codes for G and V. And yet the CFO spent the call pushing expectations down: “I don't expect it to have a material impact on the revenue in Q4.” — Håkan Johansson, Chief Financial Officer · 2026-10-22 He is almost certainly right, because the mechanism is administrative, not clinical — coders, groupers, value analysis committees. Torbjorn was blunt about the recurring friction, which he frames as permanent rather than episodic: the clinician level go-stop-go and its administrative twin, where a surgeon's rising usage triggers a purchasing review. On the old NTAP he was dismissive by comparison: “NTAP from our perspective was much -- had a much smaller reach and much less importance than CMS ruling, arguably.” — Torbjorn Skold, CEO · 2026-10-22 On the Q3 acceleration itself, Håkan was equally deflationary: “I do not think that you should see this as a sustained acceleration.” — Håkan Johansson, Chief Financial Officer · 2026-10-22The bear case got asked out loud
Buried in the Q&A was the most substantive challenge to the equity story in years: a Journal of Bone and Joint Surgery paper reanalysing the foundational 2016 Stravinskas work, arguing CERAMENT G's sustained-elution claim does not survive scrutiny. This is precisely the sort of thing the keyword map catches before the sell side publishes: mouse study, animal model, elution property of CERAMENT G.Management also flagged that several authors are affiliated with a competing antibiotics-elution company, Precision Antibiotics, and that customer feedback has been nil. Both may be true. But the strategic point stands: premium pricing at a 94% gross margin rests on a differentiated product claim, not merely an effective one. If "controlled sustained elution" degrades in the market's mind to "bone void filler with a potent antibiotic pulse," the health-economic argument to hospital administrators gets harder, not easier — and administrators are exactly the constituency the CMS ruling now empowers. There was no press coverage of this name in the window at all, in either direction.In the animal study, the bone void filler was tested in soft tissue, which is not indicated for use... the volumes were completely different, which were tested. Very, very small sizes were tested in the publication.